Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 12, 2015, Pages 2260-2261

  Van Herwaarden, Noortje ^a   Bouman, Chantal A M ^a   Van Der Maas, Aatke ^a   Van Vollenhoven, Ronald F ^b   Bijlsma, Johannes W ^c   Van Den Hoogen, Frank H J ^a,d   Den Broeder, Alfons A ^a   Van Den Bemt, Bart J F ^a,d  

^a SINT MAARTENSKLINIEK   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; ANTIRHEUMATIC AGENT;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MINIMUM PLASMA CONCENTRATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; ARTHRITIS, RHEUMATOID; BLOOD;

ADALIMUMAB; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ETANERCEPT; HUMANS;

EID: 84954403598     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207814     Document Type: Letter

References (9)

1. Vincent FB, Morand EF, Murphy K, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72:165-78.
2. Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum 2011;63:867-70.
3. Krieckaert CL, Nair SC, Nurmohamed MT, et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects. Ann Rheum Dis 2015;74:361-8.
4. van Herwaarden N, van der Maas A, Minten MJM, et al. Randomised controlled non-inferiority study of disease activity guided dose reduction and withdrawal of adalimumab and etanercept compared to usual care in rheumatoid arthritis. BMJ 2015;350:h1389.
5. Jamnitski A, Krieckaert CL, Nurmohamed MT, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88-91.
6. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
7. Ducourau E, Ternant D, Lequerre T, et al. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis 2014;73:1428-9.
8. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 2005;34(Suppl 1):12-18.
9. den Broeder AA, van der Maas A, van den Bemt BJ. Antidrug antibodies to tumour necrosis factor specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective; comment on the article by Vincent et al. Ann Rheum Dis 2013;72:e14.